Karyopharm Reports Second Quarter 2015 Financial Results and Highlights Recent Progress
August 10, 2015 07:30 ET
|
Karyopharm Therapeutics
– Positive Selinexor Clinical Data Presented across Several Difficult to Treat Cancers –
– Provides Update to Certain Trials based on Expanding Clinical Experience...
Karyopharm to Report Second Quarter 2015 Financial Results on August 10, 2015
August 03, 2015 08:00 ET
|
Karyopharm Therapeutics
NEWTON, Mass., Aug. 3, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report second quarter 2015 financial...
Karyopharm Presents Hematologic Cancer Data on Lead Drug Candidate Selinexor at International Conference on Malignant Lymphoma
June 22, 2015 07:00 ET
|
Karyopharm Therapeutics
NEWTON, Mass., June 22, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the presentation of positive clinical and...
Karyopharm Presents Hematologic Cancer Data on Lead Drug Candidate Selinexor at European Hematology Association Annual Meeting
June 15, 2015 07:00 ET
|
Karyopharm Therapeutics
NEWTON, Mass., June 15, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the presentation of positive clinical data for its...
Karyopharm Presents Clinical Data for Selinexor (KPT-330) in Patients With Recurrent Glioblastoma and Advanced Sarcomas at 2015 ASCO Annual Meeting
June 01, 2015 14:15 ET
|
Karyopharm Therapeutics
NEWTON, Mass., June 1, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the presentation of positive clinical data for its...
Karyopharm Presents Clinical Data for Selinexor (KPT-330) in Patients With Heavily Pretreated Gynecological Cancers and Asian Patients With Advanced Malignancies at 2015 ASCO Annual Meeting
May 30, 2015 14:15 ET
|
Karyopharm Therapeutics
NEWTON, Mass., May 30, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the presentation of positive clinical data for its...
Karyopharm Initiates STORM Clinical Trial of Oral Selinexor (KPT-330) in Multiple Myeloma
May 28, 2015 08:00 ET
|
Karyopharm Therapeutics
NEWTON, Mass., May 28, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the initiation of the STORM study (Selinexor...
Karyopharm to Present Clinical Data Update for Selinexor (KPT-330) in Solid Tumors
May 27, 2015 16:10 ET
|
Karyopharm Therapeutics
- Presentation to Include Discussion of Selinexor as Single-Agent in Solid Tumor Malignancies Including Gynecologic Cancers, Recurrent Glioblastoma and Advanced Sarcomas -
- Webcast Event...
Karyopharm to Present Hematologic Cancer Data on Lead Drug Candidate Selinexor at European Hematology Association Annual Meeting
May 21, 2015 07:25 ET
|
Karyopharm Therapeutics
- Presentations Include Clinical Data on Activity of Selinexor (KPT-330) in Diffuse Large B-cell Lymphoma and Acute Myeloid Leukemia -
- An Oral Presentation to Highlight the Durability of...
Karyopharm to Present Solid Tumor Data on Lead Drug Candidate Selinexor at 2015 American Society of Clinical Oncology Annual Meeting
May 13, 2015 17:00 ET
|
Karyopharm Therapeutics
NEWTON, Mass., May 13, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that four abstracts describing the activity of...